About

About ImpriMed ImpriMed is a precision oncology biotech company based in Palo Alto, California, that predicts how individual patients' cancers will respond to therapies. Our xCellSense™ platform tests live, patient-derived cancer cells against drugs and combinations ex vivo, then applies AI and outcomes-linked analytics to generate actionable treatment insights — going beyond genomics to reveal what actually works. We've built and commercially validated this approach in veterinary oncology, creating the largest known outcomes-linked functional drug response database in naturally occurring cancers, with over 12,000 canine hematologic cancer cases tied to clinical outcomes. We're now expanding into human oncology, focusing on hematologic malignancies including AML, MDS, ALL, non-Hodgkin lymphoma, and multiple myeloma, with early clinical data presented at ASH demonstrating meaningful genotype-response associations. Operating from ISO 17025-accredited labs in the US and KGMP-certified facilities in Korea, ImpriMed supports biopharma partners through CRO services that deliver comprehensive drug sensitivity reports in 4–6 weeks. We help drug developers design rational combinations, differentiate assets, and enrich clinical trials based on observed biology rather than prediction alone. We're seeking partnerships with pharma and biotech teams advancing early oncology assets where combination strategy and patient selection matter most.